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Abstract
Background: We describe the rationale and protocol for a randomized controlled trial (RCT) to assess whether
intrauterine contraception placed immediately after a second trimester abortion will result in fewer pregnancies than
current recommended practice of intended placement at 4 weeks post-abortion. Decision analysis suggests the
novel strategy could substantially reduce subsequent unintended pregnancies and abortions. This paper highlights
considerations of design, implementation and evaluation of a trial expected to provide rigorous evidence for
appropriate insertion timing and health economics of intrauterine contraception after second trimester abortion.
Methods/Design: Consenting women choosing to use intrauterine contraception after abortion for a pregnancy of
12 to 24 weeks will be randomized to insertion timing groups either immediately (experimental intervention) or
four weeks (recommended care) post abortion. Primary outcome measure is pregnancy rate at one year. Secondary
outcomes include: cumulative pregnancy rates over five year follow-up period, comprehensive health economic
analyses comparing immediate and delayed insertion groups, and device retention rates, complication rates
(infection, expulsion) and, contraceptive method satisfaction. Web-based Contraception Satisfaction Questionnaires,
clinical records and British Columbia linked health databases will be used to assess primary and secondary
outcomes. Enrolment at all clinics in the province performing second trimester abortions began in May 2010 and is
expected to complete in late 2011. Data on one year outcomes will be available for analysis in 2014.
Discussion: The RCT design combined with access to clinical records at all provincial abortion clinics, and to
information in provincial single-payer linked administrative health databases, birth registry and hospital records,
offers a unique opportunity to evaluate such an approach by determining pregnancy rate at one through five
years among enrolled women. We highlight considerations of design, implementation and evaluation of a trial
expected to provide rigorous evidence for appropriate insertion timing and health economics of intrauterine
contraception after second trimester abortion.
Trial registration: Current Controlled Trials ISRCTN19506752
Introduction
Abortion is common in Canada with 96,815 reported in
2005 [1]. Canadian women seeking abortion represent a
high risk group for recurrent unintended pregnancy as 38%
have had at least one previous abortion [2]. About 12% of
all abortions occur past the 12th week in pregnancy
(second trimester)[3,4]. Women seeking abortion in the
second trimester are disproportionately from marginalized
and vulnerable populations [3-6], and recurrent unintended
pregnancies may further exacerbate social and economic
disadvantages [7]. The most effective contraceptive is “for-
gettable”[8], that is: a method requiring user attention no
more often than every 3 years. Intrauterine contraception
(IUC) is efficacious, and thus highly effective contraception
[9-12]. Robust evidence exists to favour immediate * Correspondence: wvnorman@interchange.ubc.ca
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any medium, provided the original work is properly cited.insertion of an IUC after first trimester abortion [13-19]
and post-partum [20-23].
To minimize expulsion and potential for perforation of
the IUC device, current recommended care and product
monographs indicate delaying insertion after a second
trimester abortion until substantial uterine involution
(return to non-pregnant size): typically 4-6 weeks [24,25].
This recommendation appears to be founded upon a the-
oretical risk of greater rates for expulsion prior to uterine
involution, as we were unable to find published evidence
to support this assertion. Although the rates for both
expulsion and perforation are believed to be only margin-
ally higher than for insertion at 4 weeks [26,27], as few as
26% of women return by 6 weeks for a planned delayed
insertion [28].
British Columbia (BC) administrative health databases
track health care services provided within a single-payer
universal health care system. These databases enable a
linkage of study participant information to health system
data on all births, abortions, miscarriages, any pregnancy
related visits, hospital admissions and prescriptions dis-
pensed following study enrollment. This method can
substantially reduce attrition rate in a population known
to have low post abortion follow up adherence [27-31].
The proposed randomized controlled trial (RCT) of
immediate compared to a planned delayed device inser-
tion following second trimester abortion is the first to
examine both the levonorgestrel and the copper device
and the first to report on pregnancy rate at one year as
the primary outcome measure. The study will provide
generalizable results using an intention-to-treat frame-
work for the hypothesis: Intrauterine contraception
placed immediately after a second trimester abortion will
result in fewer pregnancies than current recommended
care of intended placement at 4 weeks post-abortion.T h e
health economic analysis of costs and cost-effectiveness
will facilitate determination of population health implica-
tions to inform health systems and health care delivery
decisions.
Methods
Study design
Women having a second trimester abortion at any BC
abortion clinic, and choosing an IUC for post-abortion
contraception will be eligible to participate in the study.
Consenting participants choose either a copper or a
levonorgestrel-releasing IUC and are then randomly
allocated to an insertion time immediately or four weeks
after their abortion. Contraception Satisfaction Ques-
tionnaires (CSQ), clinical records and the linked provin-
cial health administrative databases will be accessed to
determine all pregnancies occurring within one year of
enrollment, supplemented with a variety of secondary
outcomes.
Sample Size and Power Calculations
350 women choosing a levonorgestrel-releasing IUC
(LNG-IUC, “Mirena
®”, Bayer Inc, Canada), and 366
women choosing a “T” shaped copper IUC with 380
mm
2 surface area of copper including copper bands on
the “T” arms (CuT380-IUC, “Flexi-T380(+)
®”,P r o s a n ,
The Netherlands) will be recruited and randomly allo-
cated to each of two treatment arms: immediate inser-
tion (experimental intervention) vs. planned delayed
insertion (recommended care), representing a total
enrollment of 716 women into this Phase IIIb RCT (See
Table 1). This sample size will provide 90% power in
the levonorgestrel stratum to distinguish predicted one
year pregnancy rates of 1.2% (immediate) versus 8.7%
(delayed) and 80% power for corresponding detection of
2.7% and 9.7% in the copper device users.
Estimation of Probable Rates of Pregnancy
The pregnancy rates used in our sample size calculation
are justified as follows. The one year failure rate of the
LNG-IUC device is known to be 0.1%[32] except in the
case of spontaneous expulsion that we conservatively
estimate occurs when immediately inserted after second
trimester abortion with a probability of 0.05 (observed
rate 0.03 by Drey [27] and Cremer [29]). Our estimated
post-abortion pregnancy probability in the absence of an
IUC is 0.24 [33]. Therefore the estimated pregnancy rate
in the immediate insertion LNG-IUC group is expected
to be:
A=. 9 5× .0 1+. 0 5× .24 = .013
In the delayed group, we conservatively estimate 65%
o fw o m e nw i l lr e t u r nf o ri n s e r t i o no ft h eI U C( S t a n e k
found 26% return for planned delayed insertion [28],
and Cremer 30%[29]), and we assume (conservatively)
the high expulsion rate of the immediate insertion
group. These assumptions imply a one-year pregnancy
rate of
B=. 6 5× A+. 3 5× .24 = .092
T h eo n ey e a rf a i l u r er a t ef o rt h eC u T 3 8 0 - I U Ci s1 . 7 %
[34]. Using the above formula this yields rates for
immediate and delayed insertion of .028 and .102
respectively. Allowing for a loss to follow-up of up to
5% provides conservative estimates of the observed
Table 1 Enrollment Allocation
Immediate Delayed Total
LNG-IUC 175 175 350
CuT380-IUC 183 183 366
Total 358 358 716
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cohort and .027 and .097 in the CuT380-IUC group.
Inclusion Criteria
All women at participating study sites who have com-
pleted informed consent for an abortion over 12 and
under 24 weeks gestational age (as determined by ultra-
sound), who are residents of BC enrolled in the univer-
sal provincial medical services plan and have chosen to
use an IUC for post-abortion contraception are eligible
to participate.
Exclusion Criteria
Women are not eligible if they intend to move from BC
within the next year or if they intend to conceive within
one year. In addition, if they have a contraindication to
the use of the IUC they have chosen (see Table 2) or
are currently enrolled in another clinical trial they will
be excluded. Post randomization exclusion factors
include perforation or excessive bleeding at the time of
their abortion or uterine anomaly detected at the time
of the abortion procedure. These exclusions are
designed to be only those which, in real life, would pre-
clude a woman from being able to choose this method
of contraception. This study has no minimum age cri-
teria for enrollment.
Participating Study Clinics
All five surgical abortion clinics offering second trime-
ster abortion in the province of BC are collaborating in
this study. The geographic catchment areas for the
clinics include both urban and rural areas, and service
through these clinics is provided in both hospital and
free-standing publicly-funded outpatient settings.
Enrollment process
All women presenting to a participating clinic for an
abortion of a pregnancy over 12 weeks and under 24
completed weeks receive information on the research
study web page [35] at the time they book their appoint-
ment, and a study information brochure upon check in.
Women consenting to participate complete an initial
CSQ. Participants receive their chosen IUC at no cost in
addition to a gift card and are randomly allocated using
Table 2 Inclusion and Exclusion Criteria
Inclusion Criteria - This study will be offered to women at the study sites who meet all of the following criteria:
Have completed informed consent for an abortion over 12 and under 24 weeks gestational age.
Have chosen an IUC (either LNG-IUC or CuT380-IUC) for contraception post abortion.
Are residents of British Columbia registered with the Medical Services Plan health care system.
Exclusion Criteria
Intention to move from BC within the next year
Intention to conceive within the next year
Uterine cavity anomalies causing distortion of the endometrial canal including fibroids of more than 5 cm, excluding repaired uterine septum
Current untreated PID, Chlamydia, gonorrhea, cervicitis or lower genital tract infection (recent infection is not a contraindication to IUC insertion[35])
Wilson’s Disease (if choosing a CuT380-IUC)
Undiagnosed abnormal uterine bleeding
Known uterine or cervical malignancy or cervical dysplasia
Known or suspected progestin-dependent neoplasia, including breast cancer (if choosing a LNG-IUC)
Active liver disease or dysfunction (if choosing a LNG-IUC)
Actual benign or malignant liver tumours (if choosing a LNG-IUC)
Hypersensitivity to levonorgestrel or any of the other ingredients in the formulation or component of the container components of Mirena
® (if
choosing a LNG-IUC)
Bacterial endocarditis
Established immunodeficiency (HIV positivity is not an exclusion unless immunodeficient)
Acute malignancies affecting blood or leukemias
Recent trophoblastic disease while hCG levels are elevated
Currently enrolled in another investigational study
Post Randomization Exclusion Criteria
Failure to undergo an abortion (ie: participants who elect to continue their index pregnancy at any time subsequent to randomization)
Uterine perforation at the time of abortion
Bleeding of more than 500 cc during abortion
Uterine cavity anomalies as outlined above
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immediate or planned delayed insertion, with stratifica-
tion for device, parity and clinic site. This trial has been
registered at controlled-trials.com (ISRCTN19506752).
A pilot phase study undertook to develop, pilot test and
focus group review the CSQ from an existing validated
questionnaire [37], adapted for use in our population
and for this study, including translation into the three
most common non-English languages in our population
(Cantonese, Mandarin and Punjabi). A user-friendly
internet based format for each of the four languages and
sampling times (intake, three, six and 12 month and
annually to five years) was implemented.
Immediate insertion group protocol
Women randomized to immediate insertion have their
chosen IUC inserted by their surgeon immediately follow-
ing the abortion prior to leaving the procedure or operat-
ing room. As per standard clinic protocols all women in
both groups have polymerase chain reaction (PCR) testing
for chlamydia and gonorrhoea prior to their abortion, and
receive two grams metronidazole single observed dose as
prophylaxis against postoperative infection [38]. Women
deemed to be at higher risk of a sexually transmitted infec-
tion (as per criteria used by all BC clinics [38]), and those
with positive PCR results, receive one gram of azithromy-
cin as well. An ultrasound image of the IUC in situ is
recorded. If an ultrasound machine is not immediately
available in the operating room, arrangements are made
for an ultrasound to be performed to confirm proper IUC
position.
Delayed insertion group protocol
Women randomized to planned delayed insertion are
managed as closely as possible to standard practice. Parti-
cipants are asked to make an appointment for follow-up
and IUC insertion at 4 +/-1 weeks after the date of their
abortion. All women are offered one month of an alter-
nate contraceptive. An opportunity to return for follow-
up and IUC insertion at any study clinic is available to all
women, as per recommended post abortion delayed IUC
insertion practice. Participants who have travelled over
100 km from a study clinic are asked to make arrange-
ments for insertion in their home community. Study
participants experience conditions as close to standard
non-study delayed insertion conditions as possible. These
women receive a “SmartPayment”
® card [39] and a pre-
scription for the IUC. This permits participants to receive
t h eI U Cc o s t - f r e e( a si st h ec a s ef o rt h o s ea b l et or e t u r n
to the study clinic for insertion) and for the patient’s
pharmacy of choice to be reimbursed for the IUC. The
participant is also given a requisition for a post-insertion
ultrasound. The BC Medical Services Plan provides pay-
ment for the IUC insertion and the post-insertion
ultrasound. This procedure is designed to as closely as
possible emulate the real-life conditions each participant
w o u l de x p e r i e n c ew e r es h en o t in a research study. This
process eliminates possible bias in IUC insertion rate,
and thus pregnancy rate, were she to take home a free
study IUC or we to courier it to her designated health
care provider.
Outcome determination
CSQ are offered by mail, email or as a web-based ques-
tionnaire at 3, 6 and 12 months and annually to five years
following enrollment. The CSQ collect data on expulsion
of IUC, effectiveness and satisfaction with contraceptive
method and insertion timing assigned, any removal of
the IUC, any change to contraceptive method or inten-
tion to conceive, any interval pregnancies and their out-
comes, and any adverse events. In addition participants
are asked to arrange to return to any of the study sites or
see their primary health care provider for a follow-up
clinical examination at 3, 6 and 12 months following the
abortion. Information from clinical visits and CSQ will
be used in conjunction with BC administrative health
database information to determine outcomes.
Ethical Aspects
This study has received institutional review board
approval from the following research ethics boards: the
University of British Columbia-Children’sa n dW o m e n ’s
Research Ethics Board (H10-00306), the Interior Health
Authority Research Ethics Board (2010-028) and the
Vancouver Island Health Authority Clinical Research
Ethics Board (C2010-47). A Data and Safety Monitoring
Board has been established consisting of an Obstetrician-
Gynaecologist, a biostatistician, an expert in Population
and Public Health and database linkage research, and an
economist specializing in population health pharmaceuti-
cal economics, all from Canadian universities outside of
BC, and each being independent of all members of the
research team. Funding for this study is primarily
through grants from the Canadian Institutes for Health
Research, with pilot funding and administrative support
from the Women’s Health Research Institute, and the
University of British Columbia. Donation of 385 free
Mirena devices was provided by Bayer Inc. as their sole
contribution to the research study.
Analysis
Primary outcome will be examined in an intention-to-
treat framework as pregnancy rate at one year among
women randomized to immediate insertion compared to
women randomized to a planned insertion at 4 weeks
("delayed insertion”) for each of the two IUC devices.
For example, if women in the delayed group present for
insertion after the specified 4+/-1 week insertion
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delivery, we will insert the device at the women’s
request and her assignment for the primary analysis will
not change. Similarly if for any reason a woman
assigned to the immediate insertion group is unable to
have her insertion immediately (for example, should she
have an unattended expulsion/delivery of her pregnancy
prior to the planned surgical abortion) then insertion
will be offered at the time the woman and her physician
would normally undertake to do so, and whether or not
her insertion ever occurs, her assignment for the pur-
pose of analysis will not change. Thus our primary out-
come of pregnancy rate at one year reflects real life
conditions.
Secondary outcomes include: costs and cost effective-
ness, cumulative annual pregnancy rate, device insertion
rate, loss to follow-up; continuation of method; adverse
events (such as infection or perforation); expulsion; out-
comes among those participants who were chlamydia
positive at the time of insertion; satisfaction with IUC
chosen and with insertion timing assigned. These out-
comes will be assessed initially at one year, then annually
through the five year device effectiveness period.
Operational definition for outcome
Although our outcome of one year pregnancy rate is con-
ceptually simple, exact determination of conception dates
is clearly infeasible. Consequently our actual outcome
definition provides a pragmatic approximation based on
the varying exactitude of imputations based on provincial
Medical Service Plan billings related to abortions, miscar-
riages, still births and live births. Subsequent abortions
performed within our study clinics for enrolled partici-
pants will be noted along with specific clinical informa-
tion on pregnancy duration. For abortions performed
elsewhere such as those for BC university students study-
ing out of province, or those performed by individual
physicians at rural or remote hospitals within BC, exact
gestation may not be available. In the BC health adminis-
trative databases abortions are billed as under 7 weeks
for medical abortions, and as under 14 weeks, 14 weeks
to under 18 weeks, and 18 weeks and over for surgical
abortions. Miscarriages by definition occur anytime
under 20 weeks or are classed as still birth when over 20
weeks of gestation. Thus for subsequent pregnancies
where the specific gestation is unknown, we will consider
a pregnancy to have occurred in the first year according
to the following conservative adjustments to one year fol-
low-up dates. (see Table 3.)
Analysis methods
We will compare one year pregnancy rates using a chi-
squared test declaring significance if p < .05 and provide
95% confidence intervals for the difference in pregnancy
rates using the large sample normal approximation for
differences in proportions. This simple approach is valid
so long as no systematic difference in follow-up occurs
between groups. As a check, we will also conduct analysis
to account for partial follow-up. Since our outcome defi-
nition is essentially composite and the relevant risk peri-
ods differ by components, Kaplan-Meier estimates for
each component event will be determined and composite
estimates will be obtained by summing the estimated
cumulative event rates (calculated as 1 - the survival
function) at the time-points indicated in our operational
definitions. Confidence intervals around the difference in
these estimates will be calculated using the bootstrap.
Rates for all secondary outcomes will be calculated for
events occurring within one year following abortion, and
annually for five years, using the follow-up question-
naires, direct access to clinical follow up visit records,
and billing and procedure coding data from the admin-
istrative health system databases. Multivariate logistic
regression will be used to examine demographic, socioe-
conomic, and obstetrical factors in relationship to pri-
mary and secondary objectives.
Survey Analysis
The quantitative data from the CSQ will be analyzed using
descriptive statistics. The CSQ contain several scales pro-
viding composite scores that can be used to indicate differ-
ences in the secondary outcomes. Open ended questions
will be analyzed through content analysis focusing on key
topics.
Health Economic Analysis
Economic analysis seeks to provide comparative informa-
tion on the costs and benefits of alternative clinical strate-
gies. In this study the strategy of interest is the immediate
IUC insertion after second trimester abortion versus the
delayed insertion. The economic analysis will provide esti-
mates of the improvements in benefits associated with
such a potential health policy change, and the associated
costs.
Given the nature of the clinical condition, it would be
inappropriate for benefits to be measured using quality-
adjusted life years (QALYs). Therefore a cost-effective-
ness analysis will be conducted whereby the measure of
effect is simply the number of unintended pregnancies
prevented. The primary focus for the economic analysis
will therefore be estimating resource use and costs, with
the main measure of benefit not valued explicitly within
the analysis but a presumption that avoiding unintended
pregnancies is inherently a positive outcome.
A broad perspective will be adopted to include costs
incurred within the health care sector (such as contra-
ception, abortion, medications etc.), those incurred by
other sectors (e.g. social services for fostering and
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families. In line with the main trial, the time span for
collection of resource and cost data will be one year in
the first instance and then data collection will be
extended to five years. The process of collecting
resource use data will be undertaken separately from
data collection on unit costs. Data on use of resources
in the health and welfare sectors will be gathered from
the linked health and administrative databases of the
government of British Columbia and managed by Popu-
lation Data BC. Similarly, data on use of resources in
other sectors is also available from routine sources, with
linking of data to be performed for this work. Unit costs
will be obtained and attached to resource items in order
that a cost can be calculated for each trial participant.
Unit costs will be obtained from published sources and
centres participating in the trial.
A within-trial economic analysis will be carried out,
adopting an incremental approach in that data collection
will concentrate on resource use and outcome differences
between trial arms. As the majority of cost data are
skewed, and the mean cost of each procedure is of
importance, non-parametric bootstrapping will be used
to estimate confidence intervals around the mean costs
and benefits. To reflect the differential timing of costs
being incurred and benefits being experienced, discount-
ing will be applied according to standard guidelines.
The results will be presented as incremental cost-
effectiveness ratios (ICERs) and cost-effectiveness
acceptability curves (CEACs). The robustness of the
results will be explored using sensitivity analysis, to
investigate uncertainties in the data, the analysis meth-
ods and the generalizability of the results to other
settings.
Discussion
Anticipated Limitations
Changes in intention-to-conceive
Due to our exclusion criteria, we recruit only women
who do not intend to conceive within the first year after
enrollment. Nevertheless, in this study population with
an anticipated mean age of 24, we fully anticipate some
individuals will change their intent to conceive over the
first and subsequent study years. We will account for
this in two ways. First we ask at each CSQ (three, six
and 12 months and annually to 5 years) about the intent
to conceive, and second, we assume randomization will
distribute those who have intended pregnancies within
the study period evenly to both arms of the study.
Expulsions
Most women are aware of an IUC expulsion [40], and
should it occur, will make arrangements for alternate
contraception. This alternate contraception may be a
replacement device or a change of contraceptive method.
Each participant will be provided with a toll free number
enabling them to contact the Principal Investigator
(WVN) at any time. In addition, the study team will
monitor follow up visits, CSQ, Medical Services Plan bill-
ings and prescription records of alternate contraception
prescribed or an IUC inserted. In this manner, we believe
we will be able to estimate device expulsion rate with a
fair degree of accuracy. In order to most accurately
reflect usual contraceptive conditions in the event of an
expulsion, we are not providing a free replacement
device. We have stratified at randomization for parity, as
this may be a factor in expulsion.
Summary
This paper highlights considerations of design, imple-
mentation and evaluation of a randomized controlled
trial expected to provide rigorous evidence for appropri-
ate insertion timing and health economic considerations
for the two most common forms of intrauterine contra-
ception after second trimester abortion.
Abbreviations
BC: British Columbia, a province in Canada; CEACs: Cost-Effectiveness
Acceptability Curves; CSQ: Contraception Satisfaction Questionnaires;
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Table 3 Operational definition of a pregnancy as derived from administrative billing data
Billing Type Nominal weeks of gestation Cut-off for operational definition
Abortion (medical) < 7 weeks* 1 year + 4 weeks
Abortion (surgical) < 14 weeks 1 year + 6 weeks
Abortion (surgical) 14-18 weeks 1 year + 13 weeks
Abortion (surgical) ≥ 18 weeks 1 year + 17 weeks
Miscarriage < 20 weeks 1 year + 11 weeks
Still birth ≥ 20 weeks 1 year + 25 weeks
Live birth Birth date - GA 1 year + XX*
*In Canada, mifepristone is not available. Medication-induced abortions using methotrexate and misoprostol are offered in British Columbia up to a maximum of
49 days (7 weeks) from last menstrual period.
** Where XX = median conceptual age for live births in BC.
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